Publication Date: 2015-06-14
This book will review progress toward attaining a global consensus regarding the introduction of follow-on versions of nonbiological complex drugs (NBCD). A nonbiological complex drug is a medicinal product, not being a biological medicine, where the active substance is not a homomolecular structure but consists of different (closely related and often nano particulate) structures that cannot be isolated and fully quantitated, characterized, and/or described by state-of-the-art physicochemical analytical means and where the clinical meaning of the differences is not known. The composition, quality, and in vivo performance of NBCD are highly dependent on manufacturing processes of both the active ingredient as well as in most cases the formulation. The challenges posed by the development of follow-on versions of NBCD are illustrated in this book. It discusses how the same principles for the marketing authorization of copies of NBCD as for biosimilars could be used: the need for animal and/or clinical data and the need to show similarity in quality, safety, and efficacy. The regulatory approach of NBCD will have to take into consideration the specific characteristics of the drugs, their formulation and manufacturing process and the resulting critical attributes to achieve their desired quality, safety, and efficacy. As with the biosimilars, for the NBCD product, family-specific methods should be evaluated and applied where scientifically proven, including sophisticated quality methods, pharmacodynamic markers, and animal models.
Hardcopy ISBN: 978-3-319-16240-9
eBook ISBN: 978-3-319-16241-6
Suggested List Prices
Hardcover: $156.75 (member); $209.00 (nonmember)
eBook: $119.25 (member); $159.00 (nonmember)
View other format pricing, and order a copy on the Springer website today!
AAPS Members—Sign in to view your 25% discount token here. Then, go to the Springer website to order a copy using your token.